UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
___________

FORM 8-K
CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported)
May 30, 2008



Targeted Genetics Corporation
(Exact name of registrant as specified in its charter)
 
 
Washington
0-23930
91-1549568
(State or other jurisdiction
of incorporation)
(Commission File
Number)
(IRS Employer
Identification No.)



1100 Olive Way, Suite 100, Seattle, Washington
98101
(Address of principal executive offices)
(Zip Code)



Registrant's telephone number, including area code
(206) 623-7612



Not Applicable
(Former name or former address if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


 
 
 

Item 8.01.      Other Events.

On May 30, 2008, Targeted Genetics reported additional data from its inflammatory arthritis clinical trial. Copies of the press release and clarifying statement related to this announcement are attached as Exhibit 99.1 and Exhibit 99.2 and are incorporated into this current report by reference.
 
Item 9.01.      Financial Statements and Exhibits.

Exhibits.

99.1
Press Release of Targeted Genetics Corporation dated May 30, 2008
99.2
Clarifying Statement of Targeted Genetics Corporation dated May 30, 2008
 

 


 
 
 
 

 
 
 
 
 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
 
 
 
Targeted Genetics Corporation
 
 
 
 
 
 
Dated: June 5, 2008
By:  
/s/ David J. Poston
 
David J. Poston
 
Vice President Finance and
Chief Financial Officer


 
 
 
 
 
 
 
 

 
 
 
 
 
INDEX TO EXHIBITS



Exhibit Number
Description
 
 
99.1
Press Release of Targeted Genetics Corporation dated May 30, 2008
99.2
Clarifying Statement of Targeted Genetics Corporation dated May 30, 2008